Alnylam identifies gene to lower abdominal fat and decrease cardiovascular risk
Alnylam aims to develop a therapy that targets the INHBE gene and reduces the overall risk of T2D and coronary…
By
Alnylam aims to develop a therapy that targets the INHBE gene and reduces the overall risk of T2D and coronary…
ByThe company plans to advance ABX1100 into clinical trials in the middle of next year.
Further trials for pediatric and heart failure patients are currently ongoing.
ByA growing base of evidence suggests people are significantly more likely to develop diabetes in the months following a Covid-19…
ByThe approval is based on findings from the Phase III SURPASS programme of Mounjaro.
The alpha-1 antitrypsin deficiency (AATD) market in the US and Germany is expected to see significant growth from 2021 to…
ByLeqvio may surpass its competitors due to its administration convenience and Novartis’ close ties to cardiovascular specialists.
ByEvotec will receive undisclosed upfront, milestone and tiered royalty payments totalling up to $1bn.
Thank you for subscribing to Pharmaceutical Technology